Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: Theoretical background and practical recommendations

CNS Drugs

Volumn 27, Issue 7, 2013, Pages 545-572

  Cerovecki, Anja ^a   Musil, Richard ^a   Klimke, Ansgar ^c   Seemüller, Florian ^a   Haen, Ekkehard ^d   Schennach, Rebecca ^a   Kühn, Kai Uwe ^e   Volz, Hans Peter ^f   Riedel, Michael ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Vinzenz von Paul Hospital   (Germany)

^c Clinic for Psychiatry and Psychotherapy   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f Clinic for Psychiatry and Psychotherapy Schloss Werneck   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PROLACTIN; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SERTINDOLE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE;

BODY MASS; CLINICAL PRACTICE; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE FEEDBACK; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SUPERSENSITIVITY; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSYCHOSES, SUBSTANCE-INDUCED; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84880540083     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0079-5     Document Type: Review

References (338)

1. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77(2):69-77.
2. Chouinard G, Bradwejn J, Annable L, et al. Withdrawal symptoms after long-term treatment with low-potency neuroleptics. J Clin Psychiatry. 1984;45(12):500-2.
3. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978;135(11):1409-10.
4. Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137(1):16-21.
5. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment. Schizophr Res. 1991;5(1):21-33.
6. Goudie AJ, Smith JA, Robertson A, et al. Clozapine as a drug of dependence. Psychopharmacology (Berl). 1999;142(4):369-74.
7. Borison RL. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone: the Consensus Study Group on Risperidone Dosing. Clin Ther. 1996;18(4):592-607.
8. Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry. 2007;68(Suppl. 6):5-9.
9. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl. 2):S12-21.
10. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007;68(Suppl. 6):10-3.
11. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry. 1980;137(11):1395-8.
12. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114(1):3-13.
13. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182-217.
14. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000;24(1):125-32.
15. Andersen PH, Gingrich JA, Bates MD, et al. Dopamine receptor subtypes: beyond the D1/D2 classification. Trends Pharmacol Sci. 1990;11(6):231-6.
16. Anden NE, Carlsson A, Dahlstroem A, et al. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 1964;3:523-30.
17. Dahlstroem A, Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system: II. Experimentally induced changes in the intraneuronal amine levels of bulbospinal neuron systems. Acta Physiol Scand Suppl. 1965;Suppl. 247:1-36.
18. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61(Suppl. 3):16-21.
19. Reynolds GP. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand Suppl. 1994;380:36-40.
20. Jauss M, Krack P, Franz M, et al. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord. 1996;11(6):726-8.
21. Seeman P, Weinshenker D, Quirion R, et al. Dopamine supersensitivity correlates with D2high states, implying many paths to psychosis. Proc Natl Acad Sci USA. 2005;102(9):3513-8.
22. Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, et al. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1879-83.
23. Baumgarten HG, Grozdanovic Z. Psychopharmacology of central serotonergic systems. Pharmacopsychiatry. 1995;28(Suppl. 2):73-9.
24. Roth BL. Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994;6(2):67-78.
25. MacDonald GJ, Bartolome JM. A decade of progress in the discovery and development of 'atypical' antipsychotics. Prog Med Chem. 2010;49:37-80.
26. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1):59-67.
27. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl). 2011;213(2-3):289-305.
28. Schmidt CJ, Sorensen SM, Kehne JH, et al. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 1995;56(25):2209-22.
29. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-26.
30. Freedman R, Adams CE, Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat. 2000;20(3-4):299-306.
31. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63(6):630-8.
32. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther. 2008;117(2):232-43.
33. Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry. 2007;12(3):232-46.
34. Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 2008 Dec;107(5):1188-95.
35. Fisher A, Heldman E, Gurwitz D, et al. M1 agonists for the treatment of Alzheimer's disease: novel properties and clinical update. Ann N Y Acad Sci. 1996;777:189-96.
36. Iversen SD. Behavioural evaluation of cholinergic drugs. Life Sci. 1997;60(13-14):1145-52.
37. Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1125-43.
38. Hein L. Adrenoceptors and signal transduction in neurons. Cell Tissue Res. 2006;326(2):541-51.
39. Marcus MM, Jardemark KE, Wadenberg ML, et al. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol. 2005;8(3):315-27.
40. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1145-58.
41. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971;367:69-93.
42. Muller P, Seeman P. Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology (Berl). 1978;60(1):1-11.
43. Ekblom B, Eriksson K, Lindstrom LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl). 1984;83(3):293-4.
44. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158(3):360-9.
45. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156(6):876-84.
46. Fallon P, Dursun SM. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol. 2011;25(6):755-62.
47. Davis KL, Rosenberg GS. Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry. 1979;14(4):699-703.
48. Margolese HC, Chouinard G, Beauclair L, et al. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 2002;22(4):347-52.
49. Perenyi A, Kuncz E, Bagdy G. Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology (Berl). 1985;86(1-2):244.
50. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry. 1991;52(8):346-8.
51. Parsa MA, al-Lahham YH, Ramirez LF, et al. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol. 1993;13(2):154-5.
52. Meltzer HY. Clozapine withdrawal: serotonergic or dopaminergic mechanisms? Arch Gen Psychiatry. 1997;54(8):760-3.
53. Meltzer HY, Lee MA, Ranjan R, et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology (Berl). 1996;124(1-2):176-87.
54. Llorca PM, Penault F, Lancon C, et al. The concept of supersensitivity psychosis: the particular case of clozapine. Encephale. 1999;25(6):638-44.
55. Wadekar M, Syed S. Clozapine-withdrawal catatonia. Psychosomatics. 2010;51(4):355.
56. Ahmed S, Chengappa KN, Naidu VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry. 1998;59(9):472-7.
57. Songer DA, Schulte HM. Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine. J Clin Psychiatry. 1996;57(1):40.
58. Radford JM, Brown TM, Borison RL. Unexpected dystonia while changing from clozapine to risperidone. J Clin Psychopharmacol. 1995;15(3):225-6.
59. Llorca PM, Vaiva G, Lancon C. Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Can J Psychiatry. 2001;46(1):87-8.
60. Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry. 1995;52(12):1071-2.
61. Lu ML, Pan JJ, Teng HW, et al. Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother. 2002;36(9):1387-90.
62. Turrone P, Remington G, Kapur S, et al. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology. 2003;28(8):1433-9.
63. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57(4):406-11.
64. Goudie AJ, Cole JC, Sumnall HR. Olanzapine withdrawal/discontinuation- induced hyperthermia in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1500-3.
65. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69(Suppl. 1):4-17.
66. Buckley PF. Introduction: the art and science of switching antipsychotic medications. J Clin Psychiatry. 2007;68(Suppl. 6):4.
67. Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49-55.
68. Svensson TH, Strombom U. Discontinuation of chronic clonidine treatment: evidence for facilitated brain noradrenergic neurotransmission. Naunyn Schmiedebergs Arch Pharmacol. 1977;299(1):83-7.
69. Thoolen MJ, Hendriks JC, Timmermans PB, et al. Precipitation by yohimbine of the withdrawal syndromes of clonidine, guanfacine, and methyldopa in the spontaneously hypertensive rat. J Cardiovasc Pharmacol. 1983;5(2):224-8.
70. Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67(1):160-1.
71. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs. 2005;19(1):27-42.
72. Lin CC, Bai YM, Wang YC, et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009;29(6):529-36.
73. Linden M, Scheel T, Eich FX. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. J Psychopharmacol. 2006;20(6):815-23.
74. Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107(2-3):218-22.
75. Ganguli R, Brar JS, Garbut R, et al. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses. 2011;5(2):75-9.
76. Chen CY, Lin TY, Wang CC, et al. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry Clin Neurosci. 2011;65(1):95-7.
77. Kim CY, Chung S, Lee JN, et al. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2009;24(4):181-8.
78. Kim SH, Ivanova O, Abbasi FA, et al. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol. 2007;27(4):365-8.
79. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):714-7.
80. Lin HC, Chong MY, Lee Y, et al. Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung Med J. 2009;32(4):409-16.
81. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1978-81.
82. Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244-53.
83. Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol. 2009;19(8):562-70.
84. Pae CU, Chiesa A, Mandelli L, et al. Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. Clin Drug Investig. 2010;30(3):187-93.
85. Ryckmans V, Kahn JP, Modell S, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. 2009;42(3):114-21.
86. Sarin A, Nagpal J, Bohra NK, et al. Open labeled, randomized, switch-over study of two fixed doses (10/15 mg) of aripiprazole: to evaluate its safety and efficacy in the treatment of Indian patients of schizophrenia. Indian J Psychiatry. 2004;46(1):64-71.
87. Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry. 2007;68(3):406-9.
88. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168(9):947-56.
89. Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol. 2008;28(5):540-3.
90. Kim SW, Shin IS, Kim JM, et al. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol. 2009;24(7):565-73.
91. Hsu WY, Lee CI, Chiu NY, et al. Aripiprazole in treatment-refractory schizophrenia. J Psychiatr Pract. 2009;15(3):221-6.
92. Hughes D, Morcos M. Use of aripiprazole in treatment resistant schizophrenia. J Psychopharmacol. 2008;22(8):927-8.
93. Kuloglu M, Ekinci O, Albayrak Y, et al. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature. Arch Womens Ment Health. 2010;13(5):443-7.
94. Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32(5):243-9.
95. Mago R. Proposed strategies for successful clinical management with aripiprazole. Expert Opin Pharmacother. 2008;9(8):1279-90.
96. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-9.
97. Schering-Plough Corporation. Saphris (Asenapine) sublingual tablets: US prescribing information. http://www.spfiles.com/pisaphrisv1.pdf (Accessed 2 Feb 2012).
98. Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349-55.
99. Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138-46.
100. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36-45.
101. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106-15.
102. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492-500.
103. Dubovsky SL, Frobose C, Phiri P, et al. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry. 2012;27(5):472-82.
104. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762-84.
105. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28 Suppl. 1(2):S29-35.
106. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28 Suppl. 1(2):S4-11.
107. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl. 1):S20-8.
108. Vanda Pharmaceuticals. Fanapt (iloperidone) tablets. http://www.pharma. us.novartis.com/product/pi/pdf/fanapt.pdf (Accessed 6 Feb 2012).
109. Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28 Suppl. 1(2):S12-9.
110. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25(6):904-14.
111. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210.
112. Sunovion. Latuda (lurasidone HCl) tablets: prescribing information. Available from URL: http://www.latuda.com/LatudaPrescribingInformation.pdf (Accessed 9 Feb 2012).
113. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-36.
114. Cucchiaro J, Potkin SG, Ogasa M, et al. A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Bull. 2009;35(Suppl. 1):342-3.
115. Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2-3):101-7.
116. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-67.
117. Costa e Silva JA, Alvarez N, Mazzotti G, et al. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol. 2001;21(4):375-81.
118. Dossenbach MR, Kratky P, Schneidman M, et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry. 2001;62(Suppl 2):28-34.
119. Dossenbach MRK, Beuzen JN, Avnon M, et al. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther. 2000;22(9):1021-34.
120. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin. 2008;24(5):1399-405.
121. Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry. 2003;64(2):119-22.
122. Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry. 1998;59(11):585-8.
123. Lee CT, Conde BJ, Mazlan M, et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry. 2002;63(7):569-76.
124. Lindenmayer JP, Czobor P, Volavka J, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry. 2002;63(10):931-5.
125. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63(5):408-13.
126. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61(11):833-40.
127. Kluge M, Wehmeier PM, Dittmann RW, et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry. 2005;38(1):6-12.
128. Labelle A, Bourget D, Boulay LJ, Ellis J, Tessier P. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. J Clin Psychopharmacol. 2002;22(6):545-53.
129. Lu Z, Hu J, Chen CK, et al. Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):32-40.
130. Novick D, Haro JM, Suarez D, Marques-Teixeira J, Naber D. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study. Int Clin Psychopharmacol. 2008;23(4):203-8.
131. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry. 2003;18(5):432-40.
132. Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J Clin Psychiatry. 2006;67(10):1577-82.
133. Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. J Clin Psychiatry. 2000;61(12):912-5.
134. Delassus-Guenault N, Jegouzo A, Odou P, et al. Clozapine-olanzapine: a potentially dangerous switch: a report of two cases. J Clin Pharm Ther. 1999;24(3):191-5.
135. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685-97.
136. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-17.
137. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635-47.
138. Janssen Pharmaceuticals Inc. InvegaSustenna (paliperidone palmitate) Extended-release injectable suspension for intramuscular use. http://www.invegasustenna.com/important-product-information (Accessed 2 Oct 2012).
139. Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs. 2010;24(3):227-44.
140. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072-82.
141. Johnson & Johnson Pharmaceutical Research & Development L.L.C. Efficacy and safety of a long acting anti-psychotic versus placebo inpatients with schizophrenia. http://download.veritasmedicine.com/PDF/CR003562-CSR.pdf (Accessed 2 Oct 2012).
142. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26(2):377-87.
143. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25(10):829-45.
144. Janssen Pharmaceuticals. INVEGA SUSTENNA (paliperidone palmitate) Extended-Release Injectable Suspension for intramuscular use. Available from URL: http://www.invegasustenna.com/important-product-information (Accessed 5 May 2012).
145. Lai CH. Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report. J Neuropsychiatry Clin Neurosci. 2011;23(3):E18.
146. Teng PR, Lane HY. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone. J Neuropsychiatry Clin Neurosci. 2011;23(4):E16-7.
147. Cortese L, Caligiuri MP, Williams R, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(1):69-73.
148. Gupta S, Masand PS, Virk S, et al. Weight decline in patients switching
149. Larmo I, De Nayer A, Windhager E et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Hum Psychopharmacol. 2005;20(8):573-81.
150. Nakajima M, Terao T, Iwata N, Nakamura J. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry. 2005;38(1):17-9.
151. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 2008;24(1):21-32.
152. Moller HJ, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol. 2008;23(2):95-105.
153. Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med. 2008;6:17.
154. Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv. 1996;47(12):1382-4.
155. Kirov GK, Murray RM, Seth RV, Feeney S. Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group. Acta Psychiatr Scand. 1997;95(5):439-43.
156. Malla AK, Norman RM, Kotteda V, Zirul S. Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome. Clin Ther. 1999;21(5):806-17.
157. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005;27(12):1930-41.
158. Nakanishi S, Kunugi H, Murray RM, Nojima S, Ogawa T, Takahashi T. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. Psychiatry Clin Neurosci. 2006;60(6):751-7.
159. van Os J, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol. 2004;19(4):229-32.
160. Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Investig. 2004;24(5):275-86.
161. Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hum Psychopharmacol. 2010;25(1):37-46.
162. Marinis TD, Saleem PT, Glue P, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry. 2007;40(6):257-63.
163. Muscatello MR, Bruno A, Pandolfo G, Mico U, Settineri S, Zoccali R. Emerging treatments in the management of schizophrenia: focus on sertindole. Drug Des Devel Ther. 2010;4:187-201.
164. de Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci. 2011;261(4):231-9.
165. Berecz R, Glaub T, Kellermann M, de la Rubia A, Llerena A, Degrell I. Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient. Pharmacopsychiatry. 2000;33(1):42-4.
166. Hanisch F, Friedemann J, Pillmann F. Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation. J Psychopharmacol. 2010;24(11):1725-6.
167. Perquin LN. Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol. 2005;20(6):335-8.
168. Thomas SH, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand. 2010;122(5):345-55.
169. Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229-38.
170. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66(2-3):101-13.
171. Karayal ON, Glue P, Bachinsky M, et al. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract. 2011;17(2):100-9.
172. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23(6):595-600.
173. Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33(3):121-5.
174. Montes JM, Rodriguez JL, Balbo E, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383-8.
175. Rossi A, Vita A, Tiradritti P, Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol. 2008;23(4):216-22.
176. Stip E, Zhornitsky S, Potvin S, Tourjman V. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):997-1000.
177. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580-8.
178. Rossi A, Canas F, Fagiolini A, et al. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Postgrad Med. 2011;123(1):135-59.
179. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090-5.
180. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009;9:54.
181. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE trial. Schizophr Res. 2009;107(1):22-9.
182. Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol. 1997;7(1):51-5.
183. Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol. 2012;26(5 Suppl):15-26.
184. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37(Suppl 1):S54-64.
185. Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin. 2002;18(4):201-8.
186. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull. 2007;40(1):77-97.
187. de Leon J, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8(3):311-34.
188. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9(5):410-8.
189. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):659-65.
190. Davis JM, Leucht S. Commentary on strategies for switching antipsychotics. BMC Med. 2008;6:18.
191. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders: introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(Suppl 12):5-19.
192. Edlinger M, Wolfgang FW. Review: no evidence to support gradual over abrupt switching of antipsychotics. Evid Based Ment Health. 2006;9(1):10.
193. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res. 2005;76(2-3):267-72.
194. Miodownik C, Lerner V, Kibari A, Toder D, Cohen H. The effect of sudden clozapine discontinuation on management of schizophrenic patients: A retrospective controlled study. J Clin Psychiatry. 2006;67(8):1204-8.
195. Scheifler PL, Weiden PJ. Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications. Postgrad Med. 2006;Spec No: 45-53.
196. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205(1):119-28.
197. Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12(4):655-62.
198. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
199. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87-96.
200. Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551-64.
201. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl):5-12.
202. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18(2):63-101.
203. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-81.
204. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269-92.
205. Balle T, Perregaard J, Ramirez MT, et al. Synthesis and structure-affinity relationship investigations of 5-heteroaryl-substituted analogues of the antipsychotic sertindole. A new class of highly selective alpha(1) adrenoceptor antagonists. J Med Chem. 2003;46(2):265-83.
206. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275(1):101-13.
207. Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996;317(2-3):417-23.
208. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11):1715-26.
209. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29-39.
210. Mork A, Witten LM, Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl). 2009;206(1):39-49.
211. Knight JA, Smith C, Toohey N, Klein MT, Teitler M. Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-hydroxytryptamine7 receptor by risperidone, 9-OH-risperidone, and other inactivating antagonists. Mol Pharmacol. 2009;75(2):374-80.
212. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):553-60.
213. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2):57-73.
214. Kalkman HO, Feuerbach D, Lotscher E, Schoeffter P. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003;73(9):1151-9.
215. Cosi C, Koek W. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001;433(1):55-62.
216. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000;295(1):226-32.
217. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997;17(21):8528-35.
218. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci. 2000;20(3):1208-15.
219. Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA. 2003;100(10):6186-91.
220. Xu TX, Sotnikova TD, Liang C, et al. Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor-operated protein phosphatase gate. J Neurosci. 2009;29(45):14086-99.
221. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21(5):589-98.
222. Joseph JD, Wang YM, Miles PR, et al. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience. 2002;112(1):39-49.
223. De Mei C, Ramos M, Iitaka C, Borrelli E. Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol. 2009;9(1):53-8.
224. Rondou P, Haegeman G, Van CK. The dopamine D4 receptor: biochemical and signalling properties. Cell Mol Life Sci. 2010;67(12):1971-86.
225. Meador-Woodruff JH, Grandy DK, Van Tol HH, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology. 1994;10(4):239-48.
226. Wong AH, Van Tol HH. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1091-9.
227. Wilson JM, Sanyal S, Van Tol HH. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur J Pharmacol. 1998;351(3):273-86.
228. Pucadyil TJ, Kalipatnapu S, Chattopadhyay A. The serotonin1A receptor: a representative member of the serotonin receptor family. Cell Mol Neurobiol. 2005;25(3-4):553-80.
229. Luna-Munguia H, Manuel-Apolinar L, Rocha L, Meneses A. 5-HT1A receptor expression during memory formation. Psychopharmacology (Berl). 2005;181(2):309-18.
230. Kusserow H, Davies B, Hortnagl H, et al. Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. Brain Res Mol Brain Res. 2004;129(1-2):104-16.
231. Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res. 2008;195(1):98-102.
232. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95(1-3):158-68.
233. Sumiyoshi T, Meltzer HY. Serotonin 1A receptors in memory function. Am J Psychiatry. 2004;161(8):1505-6.
234. Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther. 2011;17(1):58-65.
235. Neal-Beliveau BS, Joyce JN, Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther. 1993;265(1):207-17.
236. Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol. 2002;453(2-3):217-21.
237. Prinssen EP, Koek W, Colpaert FC, Kleven MS. Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. Behav Pharmacol. 2000;11(3-4):299-305.
238. Shimizu S, Tatara A, Imaki J, Ohno Y. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):877-81.
239. Ohno Y, Shimizu S, Imaki J. Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci. 2009;109(4):593-9.
240. Ohno Y, Shimizu S, Imaki J, et al. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology. 2008;55(5):717-23.
241. Ohno Y, Shimizu S, Imaki J, et al. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1302-7.
242. Navailles S, De Deurwaerdère P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl). 2011;213(2-3):213-42.
243. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1159-72.
244. Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry. 1999;60(Suppl 10):15-9.
245. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466-76.
246. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.
247. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177-97.
248. Creed-Carson M, Oraha A, Nobrega JN. Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res. 2011;219(2):273-9.
249. Codony X, Vela JM, Ramirez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011;11(1):94-100.
250. Marazziti D, Baroni S, Dell'Osso MC, Bordi F, Borsini F. Serotonin receptors of type 6 (5-HT6): what can we expect from them? Curr Med Chem. 2011;18(18):2783-90.
251. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009;206(3):345-54.
252. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol. 2001;63(6):637-72.
253. Fukagawa K, Sakata T, Shiraishi T, et al. Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol. 1989;256(3 Pt 2):R605-11.
254. Yanai K, Son LZ, Endou M, et al. Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience. 1998;87(2):479-87.
255. Schwartz JC, Arrang JM, Garbarg M, Traiffort E. Histamine. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 397-405.
256. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci. 2003;4(2):121-30.
257. Mercer LP, Kelley DS, Humphries LL, Dunn JD. Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J Nutr. 1994;124(7):1029-36.
258. Watanabe T, Yanai K. Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography. Tohoku J Exp Med. 2001;195(4):197-217.
259. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes. 2001;50(2):385-91.
260. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev. 1991;71:1-51.
261. Bhargava KP, Kulshrestha VK, Santhakumari G, Srivastava YP. Mechanism of histamine-induced antidiuretic response. Br J Pharmacol. 1973;47(4):700-6.
262. Kjaer A, Knigge U, Rouleau A, Garbarg M, Warberg J. Dehydration-induced release of vasopressin involves activation of hypothalamic histaminergic neurons. Endocrinology. 1994;135(2):675-81.
263. Poulakos JJ, Gertner SB. Studies on the cardiovascular actions of central histamine H1 and H2 receptors. J Pharmacol Exp Ther. 1989;250(2):500-7.
264. Malmberg-Aiello P, Lamberti C, Ghelardini C, Giotti A, Bartolini A. Role of histamine in rodent antinociception. Br J Pharmacol. 1994;111(4):1269-79.
265. Malmberg-Aiello P, Lamberti C, Ipponi A, Hanninen J, Ghelardini C, Bartolini A. Effects of two histamine-N-methyltransferase inhibitors, SKF 91488 and BW 301 U, in rodent antinociception. Naunyn Schmiedebergs Arch Pharmacol. 1997;355(3):354-60.
266. Traiffort E, Pollard H, Moreau J, et al. Pharmacological characterization and autoradiographic localization of histamine H2 receptors in human brain identified with [125I]iodoaminopotentidine. J Neurochem. 1992;59(1):290-9.
267. Vizuete ML, Traiffort E, Bouthenet ML, et al. Detailed mapping of the histamine H2 receptor and its gene transcripts in guinea-pig brain. Neuroscience. 1997;80(2):321-43.
268. Privou C, Knoche A, Hasenohrl RU, Huston JP. The H1- and H2-histamine blockers chlorpheniramine and ranitidine applied to the nucleus basalis magnocellularis region modulate anxiety and reinforcement related processes. Neuropharmacology. 1998;37(8):1019-32.
269. Dhawan BN, Shukla R, Srimal RC. Analysis of histamine receptors in the central thermoregulatory mechanism of Mastomys natalensis. Br J Pharmacol. 1982;75(1):145-9.
270. Donoso AO, Bannza AM. Acute effects of histamine on plasma prolactin and luteininzing hormone levels in male rats. J Neural Transm. 1976;39(1-2):95-101.
271. Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R. Interactions of recombinant human histamine H(1), H (2), H (3), and H (4) receptors with 34 antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(2):145-70.
272. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983;302(5911):832-7.
273. Ookuma K, Sakata T, Fukagawa K, et al. Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res. 1993;628(1-2):235-42.
274. Schwartz JC, Arrang JM, Garbarg M, Korner M. Properties and roles of the three subclasses of histamine receptors in brain. J Exp Biol. 1986;124:203-24.
275. Haaksma EE, Leurs R, Timmerman H. Histamine receptors: subclasses and specific ligands. Pharmacol Ther. 1990;47(1):73-104.
276. Brown RE, Reymann KG. Histamine H3 receptor-mediated depression of synaptic transmission in the dentate gyrus of the rat in vitro. J Physiol. 1996;496(Pt 1):175-84.
277. Garcia M, Floran B, Arias-Montano JA, Young JM, Aceves J. Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata. Neuroscience. 1997;80(1):241-9.
278. Schlicker E, Fink K, Hinterthaner M, Gothert M. Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989;340(6):633-8.
279. Schlicker E, Fink K, Detzner M, Gothert M. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect. 1993;93(1):1-10.
280. Arrang JM, Drutel G, Schwartz JC. Characterization of histamine H3 receptors regulating acetylcholine release in rat entorhinal cortex. Br J Pharmacol. 1995;114(7):1518-22.
281. Schlicker E, Betz R, Gothert M. Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol. 1988;337(5):588-90.
282. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev. 1997;49(3):253-78.
283. Tokita S, Takahashi K, Kotani H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci. 2006;101(1):12-8.
284. Wada H, Inagaki N, Itowi N, Yamatodani A. Histaminergic neuron system: morphological features and possible functions. Agents Actions Suppl. 1991;33:11-27.
285. Ito C. Histamine H3-receptor inverse agonists as novel antipsychotics. Cent Nerv Syst Agents Med Chem. 2009;9(2):132-6.
286. Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun. 2000;279(2):615-20.
287. Coruzzi G, Pozzoli C, Adami M, et al. Strain-dependent effects of the histamine H(4) receptor antagonist JNJ7777120 in a murine model of acute skin inflammation. Exp Dermatol. 2012;21(1):32-7.
288. Hsieh GC, Chandran P, Salyers AK, et al. H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol Biochem Behav. 2010;95(1):41-50.
289. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem. 1995;64(4):1888-91.
290. Alcantara AA, Mrzljak L, Jakab RL, Levey AI, Hersch SM, Goldman-Rakic PS. Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefronto-striatal pathways. J Comp Neurol. 2001;434(4):445-60.
291. Mrzljak L, Levey AI, Goldman-Rakic PS. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA. 1993;90(11):5194-8.
292. Nathanson NM. Synthesis, trafficking, and localization of muscarinic acetylcholine receptors. Pharmacol Ther. 2008;119(1):33-43.
293. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci. 1995;15(5 Pt 2):4077-92.
294. Rouse ST, Levey AI. Muscarinic acetylcholine receptor immunoreactivity after hippocampal commissural/associational pathway lesions: evidence for multiple presynaptic receptor subtypes. J Comp Neurol. 1997;380(3):382-94.
295. Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res. 2004;145:59-66.
296. Michal P, Lysikova M, El-Fakahany EE, Tucek S. Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol. 1999;376(1-2):119-25.
297. Olianas MC, Maullu C, Onali P. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology. 1999;20(3):263-70.
298. Mrzljak L, Levey AI, Rakic P. Selective expression of m2 muscarinic receptor in the parvocellular channel of the primate visual cortex. Proc Natl Acad Sci USA. 1996;93(14):7337-40.
299. Mrzljak L, Levey AI, Belcher S, Goldman-Rakic PS. Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey. J Comp Neurol. 1998;390(1):112-32.
300. Decossas M, Bloch B, Bernard V. Trafficking of the muscarinic m2 autoreceptor in cholinergic basalocortical neurons in vivo: differential regulation of plasma membrane receptor availability and intraneuronal localization in acetylcholinesterase-deficient and -inhibited mice. J Comp Neurol. 2003;462(3):302-14.
301. Bonsi P, Martella G, Cuomo D, et al. Loss of muscarinic autoreceptor function impairs long-term depression but not long-term potentiation in the striatum. J Neurosci. 2008;28(24):6258-63.
302. Rouse ST, Edmunds SM, Yi H, Gilmor ML, Levey AI. Localization of M(2) muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus. Neurosci Lett. 2000;284(3):182-6.
303. Shen KZ, Johnson SW. Presynaptic dopamine D2 and muscarine M3 receptors inhibit excitatory and inhibitory transmission to rat subthalamic neurones in vitro. J Physiol. 2000;525(Pt 2):331-41.
304. Vilaro MT, Palacios JM, Mengod G. Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett. 1990;114(2):154-9.
305. Schambra UB, Mackensen GB, Stafford-Smith M, Haines DE, Schwinn DA. Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease. Neuroscience. 2005;135(2):507-23.
306. Spreng M, Cotecchia S, Schenk F. A behavioral study of alpha-1b adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities. Neurobiol Learn Mem. 2001;75(2):214-29.
307. Watson M, McElligott JG. Cerebellar norepinephrine depletion and impaired acquisition of specific locomotor tasks in rats. Brain Res. 1984;296(1):129-38.
308. Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl). 2004;174(1):25-31.
309. van Kammen DP, Kelley M. Dopamine and norepinephrine activity in schizophrenia. An integrative perspective. Schizophr Res. 1991;4(2):173-91.
310. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry Suppl. 1992;17:12-6.
311. Woodward DJ, Moises HC, Waterhouse BD, Yeh HH, Cheun JE. The cerebellar norepinephrine system: inhibition, modulation, and gating. Prog Brain Res. 1991;88:331-41.
312. Birnbaum S, Gobeske KT, Auerbach J, Taylor JR, Arnsten AF. A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry. 1999;46(9):1266-74.
313. Arnsten AF, Mathew R, Ubriani R, Taylor JR, Li BM. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry. 1999;45(1):26-31.
314. Ferry B, Roozendaal B, McGaugh JL. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between beta- and alpha1-adrenoceptors. J Neurosci. 1999;19(12):5119-23.
315. Ferry B, Roozendaal B, McGaugh JL. Involvement of alpha1-adrenoceptors in the basolateral amygdala in modulation of memory storage. Eur J Pharmacol. 1999;372(1):9-16.
316. Ferry B, Roozendaal B, McGaugh JL. Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala. Biol Psychiatry. 1999;46(9):1140-52.
317. Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. Br J Pharmacol. 1995;115(5):781-6.
318. Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R. Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol. 1995;116(1):1605-10.
319. Moriyama N, Nasu K, Takeuchi T, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br J Pharmacol. 1997;122(6):1009-14.
320. Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol. 1998;361(1):1-15.
321. Devauges V, Sara SJ. Activation of the noradrenergic system facilitates an attentional shift in the rat. Behav Brain Res. 1990;39(1):19-28.
322. Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science. 1985;230(4731):1273-6.
323. Sara SJ, Dyon-Laurent C, Herve A. Novelty seeking behavior in the rat is dependent upon the integrity of the noradrenergic system. Brain Res Cogn Brain Res. 1995;2(3):181-7.
324. Lakhlani PP, MacMillan LB, Guo TZ, et al. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA. 1997;94(18):9950-5.
325. Yavich L, Lappalainen R, Sirvio J, Haapalinna A, MacDonald E. Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur J Pharmacol. 1997;339(2-3):113-9.
326. Scheibner J, Trendelenburg AU, Hein L, Starke K. Alpha2-adrenoceptors modulating neuronal serotonin release: a study in alpha2-adrenoceptor subtype-deficient mice. Br J Pharmacol. 2001;132(4):925-33.
327. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology. 2000;93(5):1345-9.
328. Knaus AE, Muthig V, Schickinger S, et al. Alpha2-adrenoceptor subtypes-unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem Int. 2007;51(5):277-81.
329. Franowicz JS, Arnsten AF. Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype. Psychopharmacology (Berl). 2002;162(3):304-12.
330. Franowicz JS, Arnsten AF. Treatment with the noradrenergic alpha-2 agonist clonidine, but not diazepam, improves spatial working memory in normal young rhesus monkeys. Neuropsychopharmacology. 1999;21(5):611-21.
331. Link RE, Desai K, Hein L, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science. 1996;273(5276):803-5.
332. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M. Adrenergic alpha2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci. 1998;18(8):3035-42.
333. Imaki J, Mae Y, Shimizu S, Ohno Y. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett. 2009;454(2):143-7.
334. Marcus MM, Wiker C, Franberg O, et al. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol. 2010;13(7):891-903.
335. Kalkman HO, Loetscher E. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol. 2003;462(1-3):33-40.
336. Sallinen J, Link RE, Haapalinna A, et al. Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Mol Pharmacol. 1997;51(1):36-46.
337. Andrade R. Serotonergic regulation of neuronal excitability in the prefrontal cortex. Neuropharmacology. 2011;61(3):382-6.
338. Hagan RM, Kilpatrick GJ, Tyers MB. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology (Berl). 1993;112(1 Suppl):S68-75.